GREENLAND MINES LTD Fair Value of Long-Term Debt
GREENLAND MINES LTD (GRML) had Fair Value of Long-Term Debt of $715.30 thousand as of 2022-12-31, per its 10-K/A filed 2023-10-18.
Discontinued › Notes › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2023-10-18
- 2022-12-31: Long-term Debt, Fair Value $715.30K.
| Period end | Long-term Debt, Fair Value |
|---|---|
| 2022-12-31 | $715.30K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |